Martingale Asset Management
ANIP icon

Martingale Asset Management’s ANI Pharmaceuticals ANIP Stock Holding History

Martingale Asset Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.62M Buy
36,038
+5,297
+17% +$408K 0.07% 314
2026
Q2 		$2.54M Buy
30,741
+3,203
+12% +$257K 0.06% 341
2026
Q1 		$2.12M Buy
27,538
+4,050
+17% +$316K 0.05% 337
2025
Q4 		$1.85M Sell
23,488
-226
-1% -$19.6K 0.05% 330
2025
Q3 		$2.17M Sell
23,714
-400
-2% -$32.6K 0.05% 295
2025
Q2 		$1.57M Buy
24,114
+499
+2% +$32.5K 0.04% 356
2025
Q1 		$1.58M Sell
23,615
-2,562
-10% -$153K 0.04% 358
2024
Q4 		$1.45M Sell
26,177
-8,563
-25% -$492K 0.04% 387
2024
Q3 		$2.07M Buy
34,740
+13,719
+65% +$837K 0.05% 302
2024
Q2 		$1.34M Buy
21,021
+2,590
+14% +$168K 0.03% 388
2024
Q1 		$1.27M Buy
18,431
+1,411
+8% +$85.2K 0.03% 411
2023
Q4 		$938K Hold
17,020
– – 0.02% 464
2023
Q3 		$988K Sell
17,020
-1
-0% -$58 0.02% 437
2023
Q2 		$916K Buy
17,021
+800
+5% +$35.5K 0.02% 472
2023
Q1 		$644K Hold
16,221
– – 0.01% 555
2022
Q4 		$653K Buy
16,221
+295
+2% +$11.1K 0.01% 572
2022
Q3 		$513K Buy
15,926
+3,100
+24% +$106K 0.01% 617
2022
Q2 		$381K Buy
12,826
+2,517
+24% +$72.6K 0.01% 703
2022
Q1 		$290K Buy
10,309
+801
+8% +$29.9K ﹤0.01% 730
2021
Q4 		$439K Buy
+9,508
New +$409K 0.01% 674
2020
Q4 		– Sell
-23,809
Closed -$673K – 875
2020
Q3 		$673K Sell
23,809
-26,700
-53% -$795K 0.01% 735
2020
Q2 		$1.64M Sell
50,509
-4
-0% -$143 0.02% 592
2020
Q1 		$2.06M Buy
50,513
+10,301
+26% +$548K 0.03% 482
2019
Q4 		$2.48M Sell
40,212
-5,400
-12% -$358K 0.03% 545
2019
Q3 		$3.32M Buy
45,612
+3,001
+7% +$225K 0.03% 472
2019
Q2 		$3.5M Buy
42,611
+15,502
+57% +$1.1M 0.04% 465
2019
Q1 		$1.91M Buy
27,109
+3,800
+16% +$224K 0.02% 614
2018
Q4 		$1.05M Buy
+23,309
New +$1.22M 0.01% 706

Other funds holding ANIP

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Martingale Asset Management's ANIP Position: Q3 2026 in Review

Martingale Asset Management increased its ANI Pharmaceuticals (ANIP) stake by 17% in Q3 2026, buying an estimated $408K and bringing the position to 36,038 shares worth $2.62M. The position accounts for 0.07% of the portfolio, ranked #314.

Martingale Asset Management first reported a position in ANIP in Q4 2018 and has held it in 28 quarters since. The position peaked at $3.5M in Q2 2019. 216 funds tracked by Wall St. Rank hold ANIP as of Q3 2026.

  • Martingale Asset Management held 36,038 shares of ANI Pharmaceuticals worth $2.62M as of Q3 2026.
  • Martingale Asset Management bought 5,297 ANI Pharmaceuticals shares in Q3 2026, an estimated $408K.
  • ANI Pharmaceuticals made up 0.07% of Martingale Asset Management's portfolio in Q3 2026, its #314 holding.
  • Martingale Asset Management first reported a position in ANI Pharmaceuticals in Q4 2018 and has held it in 28 quarters since.
  • Martingale Asset Management's ANI Pharmaceuticals position peaked at $3.5M in Q2 2019.
  • 216 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2026.

Based on Martingale Asset Management's 13F filing for Q3 2026, filed 12 Nov 2026.